Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.70 |
| ▸ | AKT1 | P31749 | 4/20 | 0.70 |
| ▸ | MTOR | P42345 | 3/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.70 |
| ▸ | AKT2 | P31751 | 1/20 | 0.64 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.64 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3251576 | 0.85 | PIK3CA (0.86) | PIK3CAAKT1MTORPIK3CDPIK3CG | |
| SCHEMBL2918526 | 0.84 | PIK3CA (0.76) | PIK3CAAKT1MTORPIK3CDPIK3CG | |
| SCHEMBL2924341 | 0.83 | PIK3CA (0.74) | PIK3CAAKT1MTORPIK3CDPIK3CG | |
| SCHEMBL2926894 | 0.83 | PIK3CA (0.82) | PIK3CAAKT1MTORPIK3CDPIK3CG | |
| SCHEMBL2927504 | 0.83 | PIK3CA (1.00) | PIK3CAAKT1MTORPIK3CDPIK3CG | |
| SCHEMBL13784022 | 0.82 | PIK3CA (0.83) | PIK3CAAKT1MTORPIK3CDPIK3CG | |
| SCHEMBL2925093 | 0.81 | PIK3CA (0.82) | PIK3CAAKT1MTORPIK3CDPIK3CG | |
| SCHEMBL2919450 | 0.81 | PIK3CA (0.73) | PIK3CAAKT1MTORPIK3CDPIK3CG | |
| SCHEMBL2921077 | 0.81 | PIK3CA (0.83) | PIK3CAAKT1MTORPIK3CDPIK3CG | |
| SCHEMBL2923084 | 0.81 | PIK3CA (0.81) | PIK3CAAKT1MTORPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | claimed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163489-A1 | Inhibitors of PI3 kinase | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885AKT1 33/4885MTOR 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.